Safety and Efficacy of Mupirocin Gel in Children With Impetigo
- Conditions
- Impetigo
- Interventions
- Registration Number
- NCT04287777
- Lead Sponsor
- Reig Jofre Group
- Brief Summary
The purpose of the study is to show non inferiority in terms of safety and efficacy of topical administration BID (Twice daily) of Mupirocin Gel 20 mg/g compared to topical administration of Mupirocin Ointment 20 mg/g TID (three times daily) (Bactroban) in the treatment of impetigo in paediatric population.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 467
- Age between 18 months and 15 years at the signature of informed consent
- Impetigo susceptible to be treated with topical mupirocin and non requiring systemic antibiotic treatment (maximum of 4 different affected areas and no fever).
- Global score of Skin Infection Rating Scale (SIRS) ≥ 4, with positive value (≥ 1) in at least 3 of the 5 categories evaluated.
- Signature of informed consent by parent or legal tutor and, in case of mature minor (12 years or more), signature of informed assent.
- Patient or parent's ability to understand and fulfill with protocol requirements.
- In potentially pregnant patients, negative pregnancy urine test at baseline and use of reliable contraception double barrier methods during the trial.
- Allergy to any compound of the trial treatments
- Have received systemic treatment with antibiotics or steroids, during the week prior to the baseline visit.
- Have received topical treatment with corticosteroids, antibiotics or antifungals, during the 48 hours prior to the baseline visit.
- Primary or secondary immunodeficiency.
- Have received cytostatic or immunosuppressive treatment three months prior to baseline.
- Any skin disorder that could interfere with the evaluation of the results of impetigo, such as presence of staphylococcal or streptococcal ecthyma, cellulitis, furunculosis, acute dermatitis, contact dermatitis or impetiginized eczema.
- Diabetes mellitus.
- Infection that, in the investigator's opinion, should be treated with systemic antibiotic.
- Any medical condition which, in the investigator's opinion, contraindicates the subject's participation in the trial.
- Forecast of little cooperation, non-compliance with medical treatment or low credibility.
- Have participated in any clinical investigation with medicine within 30 days prior to basal visit.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Mupirocin ointment Mupirocin ointment Topical administration of Mupirocin ointment 20mg/g TID for 7 days. Mupirocin gel Mupirocin gel Topical administration of Mupirocin gel 20 mg/g BID for 7 days Placebo Placebo Topical administration of Placebo (ointment) TID for 7 days
- Primary Outcome Measures
Name Time Method Clinical cure as assessed by the proportion of subjects with no additional antibiotic therapy required to treat impetigo at day 8 Day 8 proportion of subjects with no additional antibiotic therapy required to treat impetigo
Clinical cure at the end of treatment by SIRS assessed by blind observer Day 8 Proportion of subjects with clinical cure at the Day 8 visit, assessed by blind observer, according to criteria described in the Protocol (SIRS \< or = 2).
- Secondary Outcome Measures
Name Time Method SIRS total score at the end of treatment and follow-up by investigator Day 8 and 14 SIRS total Score at Day 8 and Day 14 visits, assessed by the investigator
Clinical cure at the end of follow up by SIRS assessed by blind observer Day14 Proportion of subjects with clinical cure at the Day 14 visit, assessed by blind observer, according to criteria described in the protocol (SIRS \< or = 2).
Clinical cure as assessed by the proportion of subjects with no additional antibiotic therapy required to treat impetigo at day 14 Day14 proportion of subjects with no additional antibiotic therapy required to treat impetigo
Total SIRS score at the end of treatment and follow-up by blind observer Day 8 and 14 Clinical cure at the end of treatment and follow-up by investigator Day 8 and 14 Proportion of subjects with clinical cure at the Day 8 and Day 14 visits, assessed by investigator, according to protocol criteria.
Bacteriology cure at follow-up Day 14 Bacteriology eradication at the end of follow-up period according to culture at screening and follow up visits
Trial Locations
- Locations (20)
CAP Torreblanca
🇪🇸Sevilla, Andalucia, Spain
CAP La Algaba
🇪🇸Sevilla, Andalucia, Spain
CAP Vallcarca-St. Gervasi
🇪🇸Barcelona, Catalonia, Spain
CAP Corbera de Llobregat
🇪🇸Corbera De Llobregat, Catalonia, Spain
CAP Amadeu Torner
🇪🇸L'Hospitalet De Llobregat, Catalonia, Spain
CAP Mossèn Cinto Verdager
🇪🇸L'Hospitalet de Llobregat, Catalonia, Spain
CAP Florida Nord
🇪🇸L'HOspitalet de Llobregat, Catalonia, Spain
CAP Rambla Ferran
🇪🇸Lleida, Catalonia, Spain
CAP Maria Bernades
🇪🇸Viladecans, Catalonia, Spain
H.U. Sureste
🇪🇸Arganda del Rey, Madrid, Spain
Scroll for more (10 remaining)CAP Torreblanca🇪🇸Sevilla, Andalucia, Spain